Heart failure with reduced ejection fraction is a prevalent and debilitating condition associated with significant mortality and morbidity. Dapagliflozin, an SGLT2 inhibitor shows promising results in reducing cardiovascular events and improving clinical outcomes. However, Real world evidence of it’s efficacy and safety is limited. This observational study aims to study the effects of dapagliflozin in patients with heart failure with reduced ejection fraction. It expects to see reduced number of recurrent hospitalisation, cardiovascular deaths, improved NYHA class, and improvement in cardiometabolic parameters as well study the adverse effects that follows.
No takes yet. Share an insight, caveat, or question.
Bordoloi et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: